These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 27385101)
21. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Li Y; Yang Y; Lu M; Shen L Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer. Pan YQ; Ruan YY; Peng JB; Han QY; Zhang X; Lin A; Yan WH Hum Immunol; 2016 Apr; 77(4):317-24. PubMed ID: 26788811 [TBL] [Abstract][Full Text] [Related]
23. The Changes and Clinical Significance of Preoperative and Postoperative Serum CEA and CA19-9 in Gastric Cancer. Jing R; Cui M; Ju S; Pan S Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255307 [TBL] [Abstract][Full Text] [Related]
24. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1. Yang J; Tang A; Ma J; Sun X; Ming L Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773 [TBL] [Abstract][Full Text] [Related]
25. High Expression of Serum UCA1 may be a Potential Biomarker for Clinical Diagnosis of Gastric Cancer. Shan L; Liu C; Ma C Clin Lab; 2019 Sep; 65(9):. PubMed ID: 31532112 [TBL] [Abstract][Full Text] [Related]
26. [Evaluation of CA72-4 as a tumor marker in patients with gastric cancer]. Ubukata H; Katano M; Motohashi G; Kasuga T; Takemura A; Tabuchi T; Tabuchi T Gan To Kagaku Ryoho; 2003 Oct; 30(11):1821-4. PubMed ID: 14619529 [TBL] [Abstract][Full Text] [Related]
27. Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging? Lin JX; Wang W; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Zhou ZW; Li P Ann Surg Oncol; 2018 Sep; 25(9):2703-2712. PubMed ID: 29971670 [TBL] [Abstract][Full Text] [Related]
28. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Emoto S; Ishigami H; Yamashita H; Yamaguchi H; Kaisaki S; Kitayama J Gastric Cancer; 2012 Apr; 15(2):154-61. PubMed ID: 21892754 [TBL] [Abstract][Full Text] [Related]
29. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. Qiu MZ; Lin JZ; Wang ZQ; Wang FH; Pan ZZ; Luo HY; Li YH; Zhou ZW; He YJ; Xu RH Int J Biol Markers; 2009; 24(4):258-64. PubMed ID: 20082274 [TBL] [Abstract][Full Text] [Related]
30. [CA72-4 and CEA in serum and peritoneal washing in gastric cancer]. Mandorwski S; Lourenço LG; Forones NM Arq Gastroenterol; 2002; 39(1):17-21. PubMed ID: 12184160 [TBL] [Abstract][Full Text] [Related]
31. Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer. Peng W; Zhou Z; Zhong Y; Sun Y; Wang Y; Zhu Z; Jiao W; Bai M; Sun J; Lu J; Yin H Sci Rep; 2019 Dec; 9(1):19084. PubMed ID: 31836775 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872 [TBL] [Abstract][Full Text] [Related]
33. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer. Gwak HK; Lee JH; Park SG Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567 [TBL] [Abstract][Full Text] [Related]
34. [Significance of CA72-4 as a follow up of recurrent gastric cancer--comparison with CEA and CA19-9]. Takahashi Y; Mai M Gan To Kagaku Ryoho; 1992 Apr; 19(4):515-8. PubMed ID: 1558402 [TBL] [Abstract][Full Text] [Related]
35. Preoperative serum CEA and CA19-9 in gastric cancer--a single tertiary hospital study of 1,075 cases. Zhou YC; Zhao HJ; Shen LZ Asian Pac J Cancer Prev; 2015; 16(7):2685-91. PubMed ID: 25854347 [TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of serum tumor markers in various pathologic subtypes of gastric cancer. Pang C; Ma Y; Shi W; Zi M; Chen J; Liang C; Li X; Liu Z; Du Y J Gastrointest Surg; 2024 May; 28(5):694-702. PubMed ID: 38458911 [TBL] [Abstract][Full Text] [Related]
37. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. Qiu Y; He J; Chen X; Huang P; Hu K; Yan H Clin Chim Acta; 2018 May; 480():186-192. PubMed ID: 29438681 [TBL] [Abstract][Full Text] [Related]
38. Advances in Molecular Biomarkers for Gastric Cancer. Zheng TH; Zhao JL; Guleng B Crit Rev Eukaryot Gene Expr; 2015; 25(4):299-305. PubMed ID: 26559090 [TBL] [Abstract][Full Text] [Related]
39. Value of combined serum CEA, CA72-4, and CA19-9 marker detection in diagnosis of colorectal cancer. Kildusiene I; Dulskas A; Smailyte G Tech Coloproctol; 2024 Feb; 28(1):33. PubMed ID: 38358422 [TBL] [Abstract][Full Text] [Related]
40. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy. Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]